Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US3755581036
Ticker GILD
Company GILEAD SCIENCES
Currency $
Price
Aware Investor Index (AII) 56.4154
Recommendation STRONG BUY
P/E 13.52
ROE 31.38 %
Capitalization 86,974,860,000 $
Dividend Yield 3.15 %
P/S 3.33
AII Position 46
P/E Position 123
ROE Position 85
Capitalization Position 96
Dividend Yield Position 217
Sales 26,107,000,000 $
10-Year Average Earnings 6,432,392,200 $
Shares Outstanding 1,319,000,000
Equity 20,501,000,000 $
Dividend per Share 2.08 $
Industry Biotechnology
Country United States
GILEAD SCIENCES Investor Relations Web Site http://investors.gilead.com







Sales:

YEAR MONTH AMOUNT
2017 12 26,107,000,000.00 $
2016 12 30,390,000,000.00 $
2015 12 32,639,000,000.00 $
2014 12 24,890,000,000.00 $
2013 12 11,201,680,000.00 $
2012 12 9,702,000,000.00 $
2011 12 8,385,000,000.00 $
2010 12 7,949,000,000.00 $
2009 12 7,011,000,000.00 $
2008 12 5,336,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 4,628,000,000.00 $
2016 12 13,501,000,000.00 $
2015 12 18,108,000,000.00 $
2014 12 12,101,000,000.00 $
2013 12 3,074,808,000.00 $
2012 12 2,591,566,000.00 $
2011 12 2,803,637,000.00 $
2010 12 2,901,257,000.00 $
2009 12 2,635,755,000.00 $
2008 12 1,978,899,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 20,501,000,000.00 $
2016 12 19,363,000,000.00 $
2015 12 19,113,000,000.00 $
2014 12 15,819,000,000.00 $
2013 12 11,744,501,000.00 $
2012 12 9,550,869,000.00 $
2011 12 6,867,349,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 1,319,000,000
2016 12 1,358,000,000
2015 12 1,521,000,000
2014 12 1,647,000,000
2013 12 1,694,747,000
2012 12 1,582,549,000
2011 12 1,580,236,000

 












Bloomberg News for GILEAD SCIENCES:



Google News for GILEAD SCIENCES:

Seeking Alpha - 9 hours ago
Gilead's Mousetrap
... is hailed as a Gilead's (NASDAQ:GILD) acquisition target while fraught with ... Gilead, Conatus, Galectin, I speculated that Gilead Sciences' ...
WestNewsNow - 7 hours ago
How Resilient are the Fundamentals: Gilead Sciences (GILD)
[NASDAQ: GILD]: On February 14th, 2019, Gilead Sciences (NASDAQ:GILD) opened trading at $66.13 and closed at $66.37 a share. This is a ...
MONReport
Gilead Could Be The Winner From Washington State's Winner-Take ...
This could be a great deal for Gilead Sciences (GILD), which has been continually battered from falling sales in its Hepatitis C line.
The Hi New Ulm
Gilead: What Just Happened?
Gilead Sciences (NASDAQ:GILD) reported Q4 2018 revenue of $5.8 billion, beating on revenue by $280 million. It missed on GAAP EPS and ...
Fairfield Current
Analyzing Titan Pharmaceuticals (TTNP) and Gilead Sciences (GILD)
Titan Pharmaceuticals (NASDAQ:TTNP) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior stock?
Seeking Alpha - 1 day ago
Gilead Sciences (GILD) Phase 3 STELLAR-4 Study of Selonsertib in ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study ...
Seeking Alpha - 23 hours ago
UPDATE: Citi Downgrades Gilead Sciences (GILD) to Neutral
Citi analyst Robyn Karnauskas downgraded Gilead Sciences (NASDAQ: GILD) from Buy to Neutral with a price target of $75.00 (from $100.00).
Fairfield Current - 11 hours ago
Two Stocks To Tuck Away: Gilead Sciences, Inc. (GILD), Pioneer ...
The shares of Gilead Sciences, Inc. (NASDAQ:GILD) has been pegged with a rating of Market Perform by Wells Fargo in its latest research note ...
StreetInsider.com - 4 days ago
Gilead Sciences'(GILD) CEO Gregg Alton on Q4 2018 Results ...
Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2018 Earnings Conference Call February 4, 2019 4:30 PM ET. Company Participants. Sung Lee ...
Seeking Alpha
Gilead: What A Difference An O'Day Can Make
Gilead Sciences (GILD) is about to get its third CEO in less than 9 weeks on or about March 1; he will be the fourth CEO in three years. Daniel ...


Back